Scancell HoldingsSCNLF 20 PEG Ratio is 0.00 as of Jun. 27, 2026. GuruFocus rates SCNLF with a GF Score™ of 20/100. The stock has 2 warning signs investors should review. Among 95 Biotechnology companies, Scancell Holdings ranks worse than 1052630.53% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Scancell Holdings's PEG Ratio or its related term are showing as below:
SCNLF's PEG Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.92 * Ranked among companies with meaningful PEG Ratio only.
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Scancell Holdings (OTCPK:SCNLF) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Scancell Holdings PEG Ratio Related Terms
Scancell Holdings PEG Ratio Historical Data
* Premium members only.
The historical data trend for Scancell Holdings's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Scancell Holdings's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scancell Holdings PEG Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Scancell Holdings's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Scancell Holdings's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Scancell Holdings (SCNLF) has a PEG Ratio of 0.00 as of Jun. 27, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Scancell Holdings and its competitors. According to the industry distribution chart, Scancell Holdings ranks #999999 out of 95 companies in the Biotechnology industry.
Is Scancell Holdings' PEG Ratio too high?
Scancell Holdings' current PEG Ratio is 0.00. Based on the distribution chart, Scancell Holdings ranks #999999 out of 95 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Scancell Holdings has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Scancell Holdings' PEG Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Scancell Holdings ranks #999999 out of 95 companies for PEG Ratio. This places Scancell Holdings in the lower half of its industry. The industry median PEG Ratio is 1.92. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Biotechnology company?
The median PEG Ratio among Biotechnology companies is 1.92, based on 95 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Scancell Holdings and its competitors. For the Biotechnology industry, the median PEG Ratio is 1.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scancell Holdings's current PEG Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scancell Holdings stock overvalued right now?
Scancell Holdings (SCNLF) has a current PEG Ratio of 0.00. The current PEG Ratio is 0.00. Scancell Holdings' overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Scancell Holdings (SCNLF), the current PEG Ratio is 0.00 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans.
20GF Score
Get the complete analysis for SCNLF
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SCNLF has been successfully added to your 
